A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 9, Issue 4, 2009, Pages 392-398

  Poh, Z X ^a   Goh, K P ^a  

^a ALEXANDRA HOSPITAL   (Singapore)

Author keywords

ALA; Anti oxidant; Diabetes; Insulin resistance; Neuropathy; Radical

Indexed keywords

ANTIOXIDANT; FATTY ACID; INSULIN; THIOCTIC ACID;

ANTIOXIDANT ACTIVITY; DIABETIC NEUROPATHY; DIABETOGENESIS; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; VERTIGO; VOMITING;

ANTIOXIDANTS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DYSLIPIDEMIAS; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; ISLETS OF LANGERHANS; KIDNEY FAILURE; LIVER FAILURE; OXIDATIVE STRESS; THIOCTIC ACID;

EID: 75749093374     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153009789839147     Document Type: Review

References (85)

1. Reed, L.J. (2001) A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. J. Biol. Chem., 276, 38329-38336.
2. Smith, A.R.; Shenvi, S.V.; Widlansky, M.; Suh, J.H. and Hagen, T.M. (2004) Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem., 11, 1135-1146.
3. Lester, P.; Peter, R.; Tristschler, H.J.; King, G.L.; Azzi, A. (2000) Antioxidants in Diabetes Management. New York NY: Marcel Dekker, Inc.
4. Bustamante, J.; Lodge, J.K.; Marcocci, L.; Tritschler, H.J.; Packer, L. and Rihn, B.H. (1998) Alpha-lipoic acid in liver metabolism and disease. Free Radic. Biol. Med., 24, 1023-1039.
5. Jakuss, V. (2000) The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease. Bratisl. Lek. Listy., 101, 541-551.
6. Halliwell, B. and Gutteridge, J.M.C.; Eds. (1999) Free Radicals in Biology and Medicine, Oxford University Press: New York.
7. Sies, H. Ed. (1991) Oxidative Stress II: Oxidants and Antioxidants, Academic Press: London.
8. Harman, D. (1981) The aging process. Proc. Natl. Acad. Sci. USA, 78, 7124-7128.
9. Harman, D. (1956) Aging: a theory based on free radical and radiation chemistry. Gerontology, 11, 298-300.
10. Ozawa T. (1997) Genetic and functional changes in mitochondria associated with aging. Physiol. Rev., 77, 425-464.
11. Lenaz, G. (1998) Role of mitochondria in oxidative stress and aging. Biochim. Biophys. Acta, 1366, 53-67.
12. Chance, B.; Sies, H. and Boveris, A. (1979) Hydroperoxide metabolism in mammalian organs. Physiol. Rev., 59, 527-605.
13. Suh, J.H.; Shenvi, S.V.; Dixon, B.M.; Liu, H.; Jaiswal, A.K.; Liu, R.M. and Hagen. T.M. (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl. Acad. Sci. USA, 101, 3381-3386.
14. Suh, J.H.; Wang, H.; Liu, R.M.; Liu, J. and Hagen, T.M. (2004) (R)-alpha-lipoic acid reverses the age-related loss in GSH redox status in post-mitotic tissues: evidence for increased cysteine requirement for GSH synthesis. Arch. Biochem. Biophys., 423, 126-135.
15. Lester, P. and Eric, H. (1995) Witt and Hans Jürgen Tritschler alpha lipoic acid as a biological antioxidant. Free Radic. Biol. Med., 19, 227-250.
16. Kozlov, A.V.; Gille, L.; Staniek, K. and Nohl, H. (1999) Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch. Biochem. Biophys., 363, 148-154.
17. Jones, W.; Li, X.; Qu, Z.C.; Perriott, L.; Whitesell, R.R. and May, J.M. (2002) Uptake, recycling, and antioxidant actions of alphalipoic acid in endothelial cells. Free Radic. Biol. Med., 33, 83-93.
18. Ou, P.; Tritschler, H.J. and Wolff, S.P. (1995) Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem. Pharmacol., 50, 123-126.
19. Suh, J.H.; Zhu, B.Z.; deSzoeke, E.; Frei, B. and Hagen, T.M. (2004) Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes. Redox Rep., 9, 57-61.
20. Suh, J.H.; Moreau, R.; Heath, S.H. and Hagen, T.M. (2005) Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep., 10, 52-60.
21. Biewenga, G.P.; Haenen, G.R. and Bast, A. (1997) The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol., 29, 315-331.
22. Konrad, D.; Somwar, R.; Sweeney, G.; Yaworsky, K.; Hayashi, M.; Ramlal, T. and Klip, A. (2001) The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 Translocation and GLUT4 Activation. Diabetes, 50, 1464-1471.
23. Konrad, D. (2005) Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation? Antioxid. Redox Signal, 7, 1032-1039.
24. Packer, L. (1998) Alpha-Lipoic acid: a metabolic antioxidant which regulates NF-kappa B signal transduction and protects against oxidative injury. Drug Metab. Rev., 30, 245-275.
25. Mark, F.; McCarty, B.A. and Keith, I. (2006) Block, preadministration of high-dose salicylates, suppressors of NF-êB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal. Modulation Ther. Integr. Cancer Ther., 5, 252-268
26. Zhang, W.J. and Frei B. (2001) Alpha-lipoic acid inhibits TNFalpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J., 15, 2423-2432.
27. Hermann, R.; Niebch, G.; Borbe, H.O.; Fieger-Büschgesf H.; Ruus, P.; Nowak, H.; Riethmüller-Winzen, H.; Peukert, M. and Blume H. (1996) Enantioselective pharmacokinetics and bioavailability of different racemic alpha-lipoic acid formulations in healthy volunteers. Eur. J. Pharm. Sci., 4, 167-174.
28. Gleiter, C.H.; Schug, B.S.; Hermann, R.; Elze, M.; Blume, H.H. and Gundert-Remy, U. (1996) Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur. J. Clin. Pharmacol., 50, 513-514.
29. Uma, S. and Ishwarlal, J. (2008) Alpha-lipoic acid supplementation and diabetes. Nutr. Rev., 66, 646-657.
30. Borcea, V.; Nourooz-Zadeh, J.; Wolff, S.P.; Klevesath, M.; Hofmann, M.; Urich, H.; Wahl, P.; Ziegler, R.; Tritschler, H.; Halliwell, B. and Nawroth, P.P. (1999) Alpha Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic. Biol. Med., 26, 1495-1500.
31. Teichert, J.; Hermann, R.; Ruus, P. and Preiss, R. (2003) Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J. Clin. Pharmacol., 43, 1257-1267.
32. Teichert, J.; Tuemmers, T.; Achenbach, H.; Preiss, C.; Hermann, R.; Ruus, P. and Preiss, R. (2005) Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease. J. Clin. Pharmacol., 45, 313-328.
33. Juanita, B.A.; John, K.; Lodge, A.; Lucia, M.A.; Hans, J.; Tritschler, B.; Lester, P.A.; Bertrand, H. and Rihn, A. (1998) α-Lipoic acid in liver metabolism and disease. Free Radic. Biol. Med., 24, 1023-1039.
34. Bartter, F.C.; Berkson, B.M.; Galleli, J. and Hiranaka, P. (1980) Thiotic Acid in the Treatment of Poisoning with Alpha-Amanitin. In: Faulstich, H.; Kommerell, B.; Wieland, T. Eds. Amanita Toxins and Poisoning. Baden-Baden Germany: Verlg, Gerhard Witzstrock; pp. 197-202.
35. Berkson, B.M. (1999) A conservative triple antioxidant approach to the treatment of hepatitis C. combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med. Klin (Munich), 94, 84-89.
36. Evans, J.L.; Youngren, J.F. and Goldfine, I.D. (2004) Effective treatments for insulin resistance: Trim the fat and douse the fire. Trends Endocrionol. Metab., 15 (9), 425-431.
37. Hotamisligil, G.S. and Spiegelman, B.M. (1994) Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 43, 1271-1278.
38. Ceriello, A. and Motz, E. (2004) Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler. Thromb. Vasc. Biol., 24, 816-823.
39. Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). (1998) UK Prospective. Lancet, 352, 837-853.
40. Douglas, A.; Greene, S.A. and Littmer, A.A.F. (1988) Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Perspect. Diabetes, 37, 688-693.
41. Greene, D.A.; DeJesus, P.V. and Winegrad, A.l. (1975) Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocln diabetes. J. Clin. Invest., 55, 1326-1336.
42. Mayer, J.H. and Tomlinson, D.R. (1983) Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase lnhlbltor 11- streptozotocin-dlabetlc rats. Diabetologia, 25, 433-438.
43. Stevens, M.J.; Lattimer, S.A.; Kamijo, M.; Van Huysen, C.; Sima, A.A. and Greene, D.A. (1993) Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia, 36, 608-614.
44. Cameron, N.E.; Eaton, S.E.; Cotter, M.A. and Tesfaye, S. (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44, 1973-1988.
45. Dinçer, Y.; Akçay, T.; lkova, H.; Alademir, Z. and Özbay, G. (2003) DNA damage and antioxidant defense in peripheral leukocytes of patients with Type I diabetes mellitus. Mutat. Res., 527, 49-55.
46. Erika, S.; József, P.; János, F. and Anikó, S. (1999) Alterations in enzymatic antioxidant defence in diabetes mellitus a rational approach. Postgrad. Med. J., 75, 13-17.
47. Andreeva-Gateva, P.; Popova, D. and Orbetsova, V. (2001) Antioxidant parameters in metabolic syndrome - a dynamic evaluation during oral glucose tolerance test. Vutr. Boles., 33, 48-53. [48] Oberley, L.W. (1988) Free radicals and diabetes. Free Radic. Biol. Med., 5, 113-124.
48. Rösen, P.; Nawroth, P.P.; King, G.; Möller, W.; Tritschler, H.J. and Packer, L. (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 17, 189-212.
49. Bonnefont-Rousselot, D. (2002) Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care, 5, 561-568. [51] Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820.
50. Varma, S.D.; Devamanoharan, P.S. and Ali, A.H. (1997) Formation of advanced glycation end (AGE) products in diabetes: prevention by pyruvate and á-ketoglutarate. Mol. Cell. Biochem., 171, 23-28.
51. Dorota, Z. and Bogna, W.-W. (2005) Hyperglycaemia and Inflammation are culprits of late diabetic complications. Arch. Med. Sci., 1, 115-118.
52. Evans, J.L.; Goldfine. I.D.; Maddux, B.A. and Grodsky, G.M. (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr. Rev., 23, 599-622.
53. Jacob, S.P.; Ruus, R.; Hermann, H.J.; Tritschler, E.; Maerker, W.; Renn, H.J.; Augustin, G.J. and Rett, K. (1999) Oral administration of rac-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo controlled pilot trial. Free Radic. Biol. Med., 27(3-4), 309-314.
54. Jacob, S.; Ruus, P.; Hermann, R.; Tritschler, H.J.; Maerker, E.; Renn, W.; Augustin, H.J.; Dietze, G.J. and Rett, K. (1999) Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol. Med., 27(3-4), 309-314.
55. Kamenova, P. (2006) Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alphalipoic acid. Hormones (Athens), 5, 251-258.
56. Midaoui, A.E.L. and Jacques de Champlain. (2002) Prevention of hypertension, insulin resistance and oxidative stress by alpha-lipoic acid. Hypertension, 39, 303-307.
57. Jacob, S.; Henriksen, E.J.; Schiemann, A.L.; Simon, I.; Clancy, D.E.; Tritschler, H.J.; Jung, W.I.; Augustin, H.J. and Dietze, G.J. (1995) Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneimittelforschung, 45, 872-874.
58. Karen, S. and William, C. (2002) Gong. Natural products used for Diabetes. J. Am. Pharm. Assoc., 42, 217-226.
59. Blerina, K.; Marco, B.; Rutter, G.A.; Grossman, A.B. and Korbonits, M. (2004) Expanding role of AMPK in endocrinology. Trends Endocrionol. Metab., 17, 58.
60. Kahn, B.B.; Alquier, T.; Carling, D. and Hardie, D.G. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell. Metab., 1, 15-25.
61. Richter, E.A.; Derave, W. and Wojtaszewski, J.F. (2001) Glucose, exercise and insulin: emerging concepts. J. Physiol., 535, 313-322.
62. Hardie, D.G.; Scott, J.W.; Pan, D.A. and Hudson, E.R. (2003) Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett., 546, 113-120.
63. Kola, B.; Boscaro, M.; Rutter, G.A.; Grossman, A.B. and Korbonits, M. (2006) Expanding role of AMPK in endocrinology. Trends Endocrinol. Metab., 17, 205-215.
64. Cameron, N.E. and Cotter, MA. (1997) Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes, 46, S31-S37.
65. Sima, A.A.F. (2001). Diabetic neuropathy: pathogenetic background, current and future therapies. Expert Rev. Neurother., 1, 225-238.
66. Kenneth, C. Jackson II. (2006) Pharmacotherapy for Neuropathic Pain. Pain Practice. Blackwell Publishing. Volume 6 (Issue 1) pp. 27-33.
67. Bouton, A.J.; Viniki, A.I.; Arezzo, J.C.; Bril, V.; Feldman, E.L.; Freeman, R.; Malik, R.A.; Maser, R.E.; Sosenko, J.M. and Ziegler, D. Diabetic Neuropathies A statement by the American Diabetes Association. Diabetes Care, 28, 956-962. 2005.
68. Rosenstock, J.; Tuchman, M.; LaMoreaux, L. and Sharma, U. (2004) Pregabalin for the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled trial. Pain, 110, 628-638.
69. Goldstein, D.J. (2006) Duloxetine in the treatment of diabetic peripheral neuropathic pain. Future Neurol., 1, 701-711.
70. Vinik, A. and Mehrabyan, A. (2004) Diabetic neuropathies. Med. Clin. N. Am., 88, 947-999.
71. Misha-Miroslav, B. and Serra, J. (2004) Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med., 5, S28-S47.
72. Haak, E.; Usadel, K.H.; Kusterer, K.; Amini, P.; Frommeyer, R.; Tritschler, H.J. and Haak, T. (2000) Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp. Clin. Endocrinol. Diabetes, 108, 168-174.
73. Ziegler, D.; Schatz, H.; Conrad, F.; Gries, F.A.; Ulrich, H. and Reichel, G. (1997) Effects of treatment with the antioxidant alphalipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multi-centre trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care, 20, 1918-1920.
74. Ziegler, D.; Hanefeld, M.; Ruhnau, K.J.; Meissner, H.P.; Lobisch, M.; Schütte, K. and Gries, F.A. (1995) Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia, 38, 1425-1433.
75. Reljanovic, M.; Reichel, G.; Rett, K.; Lobisch, M.; Schuette, K.; Möller, W.; Tritschler, H.J. and Mehnert, H. (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alphalipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II): alpha lipoic acid in diabetic neuropathy. Free Radic. Res., 31, 171-179.
76. Ametov, A.S.; Barinov, A.; Dyck, P.J.; Hermann, R.; Kozlova, N.; Litchy, W.J.; Low, P.A.; Nehrdich, D.; Novosadova, M.; O'Brien, P.C.; Reljanovic, M.; Samigullin, R.; Schuette, K.; Strokov, I.; Tritschler, H.J.; Wessel, K.; Yakhno, N.; Ziegler, D. and SYDNEY Trial Study Group. (2003) The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care, 26, 770-776.
77. Ruhnau, K.J.; Meissner, H.P.; Finn, J.R.; Reljanovic, M.; Lobisch, M.; Schütte, K.; Nehrdich, D.; Tritschler, H.J.; Mehnert, H. and Ziegler D. (1999) Effects of 3-week oral treatment with the antioxidant thioctic acid (á-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med., 6, 1040-1043.
78. Ziegler, D.; Reljanovic, M.; Mehnert, H. and Gries, F.A. (1999) Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes, 107, 421-430.
79. Ziegler, D.; Ametov, A.; Barinov, A.; Dyck, P.J.; Gurieva, I.; Low, P.A.; Munzel, U.; Yakhno, N.; Raz, I.; Novosadova, M.; Maus, J. and Samigullin, R. (2006) Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 29, 2365-2370.
80. Takeuchi, Y.; Miyamoto, T.; Kakizawa, T.; Shigematsu, S. and Hashizume, K. (2007) Insulin autoimmune syndrome possibly caused by alpha lipoic acid. Intern. Med., 46(5), 237-239.
81. Furukawa, N.; Miyamura, N.; Nishida, K.; Motoshima, H.; Taketa, K. and Araki, E. (2007) Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome. Diabetes Res. Clin. Pract., 75(3), 366-367.
82. Yasuko, I. and Yukimasa, U. (1999) HIRATA. Insulin autoimmune syndrome (IAS, Hirata disease)1. Ann. Med. Interne (Paris)., 150, 245-253.
83. Yoshihiko, I.; Takeshi, O.; Yoko, O.; Tatsuo, I.; Yushi, H.; Kensuke, F.; Kazuhiko, S.; Wataru, O. and Masato, K. (2007) Alpha-lipoic and insulin autoimmune syndrome. Diabetes Care, 30, 2240-2241.
84. Uchigata, Y.; Hirata, Y.; Omori, Y.; Iwamoto, Y. and Tokunaga, K. (2006) Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum. Immunol., 61, 154-157.
85. Ziegler, D. (2004) Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat. Endocrinol., 3, 173-189.